TOVX - CONSENSUS CO - Theriva Biologics, Inc.

The development of anti-tumor modified adenoviruses by Theriva Biologics, Inc. (TOVX) relies on strict patent protection and the availability of sophisticated laboratories. Anticipation of trial results for pancreatic treatment drugs at the current price of 2.50 serves as the primary driver. The status of a preclinical startup implies a lack of profit and high capital expenditure. This chart of the TOVX price trend clearly demonstrates the market dynamics of this biotech project.

This metric synthesizes weighted average target values from industry experts, filtering out market noise to identify the long-term vector of fundamental value. By analyzing the analysts' consensus price target, an investor can see how the market is pricing in risks for Theriva Biologics, Inc. (TOVX) related to clinical trial uncertainty and capital shortages amid fierce competition in the biopharmaceutical sector.